Premium
Mycophenolate Mofetil as an Adjuvant Therapy for Classic and Endemic Pemphigus Foliaceus
Author(s) -
Kawashita Milka Yuri,
Tsai Katia,
Aoki Valéria,
Santi Claudia Giuli,
Maruta Celina Wakisaka,
Rivitti Evandro
Publication year - 2005
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.2005.tb00801.x
Subject(s) - pemphigus foliaceus , medicine , desmoglein 1 , pemphigus , mycophenolate , dermatology , adverse effect , autoimmune disease , pemphigus vulgaris , autoantibody , adjuvant , refractory (planetary science) , immunology , disease , antibody , biology , transplantation , astrobiology
Pemphigus foliaceus is an autoimmune cutaneous disease with subcorneal acantholysis and pathogenic IgG4 autoantibodies directed against desmoglein 1. We present our experience with mycophenolate mofetil (MMF) in the treatment of one case of endemic pemphigus foliaceus (fogo selvagem) and two cases of the classic form. All patients had severe, refractory disease and developed marked adverse effects due to long‐term corticosteroid therapy. MMF proved to be an effective corticosteroid‐sparing agent at doses varying from 35 to 45 mg/kg/d. It was well tolerated, and we found no significant adverse effects from this drug.